These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12121952)

  • 1. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.
    Pérez-Trallero E; García-Rey C; Martín-Sánchez AM; Aguilar L; García-de-Lomas J; Ruiz J;
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2665-7. PubMed ID: 12121952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
    Fuentes F; Giménez MJ; Marco F; Alou L; Aguilar L; Prieto J
    Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):137-9. PubMed ID: 10746503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.
    Sadowy E; Izdebski R; Skoczyńska A; Gniadkowski M; Hryniewicz W
    Antimicrob Agents Chemother; 2005 May; 49(5):2126-9. PubMed ID: 15855545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.
    Weiss K; Restieri C; Gauthier R; Laverdière M; McGeer A; Davidson RJ; Kilburn L; Bast DJ; de Azavedo J; Low DE
    Clin Infect Dis; 2001 Aug; 33(4):517-22. PubMed ID: 11462189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
    Zhanel GG; Palatnick L; Nichol KA; Bellyou T; Low DE; Hoban DJ
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1867-74. PubMed ID: 12760860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.
    Piddock LJ; Johnson M; Ricci V; Hill SL
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2956-60. PubMed ID: 9797232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):199-201. PubMed ID: 9401813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.
    Heaton VJ; Goldsmith CE; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2998-3000. PubMed ID: 10582896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones.
    Alou L; Ramirez M; García-Rey C; Prieto J; de Lencastre H
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2955-7. PubMed ID: 11557501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
    Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Mar; 44(3):598-601. PubMed ID: 10681324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.
    Low DE; de Azavedo J; Weiss K; Mazzulli T; Kuhn M; Church D; Forward K; Zhanel G; Simor A; McGeer A
    Antimicrob Agents Chemother; 2002 May; 46(5):1295-301. PubMed ID: 11959559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
    Davies TA; Kelly LM; Pankuch GA; Credito KL; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of six fluoroquinolones against invasive Streptococcus pneumoniae isolated from 1996 to 2001 in Taiwan.
    Chen JY; Fung CP; Wang CC; Chu ML; Siu LK
    Microb Drug Resist; 2003; 9(2):211-7. PubMed ID: 12820807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
    Wise R; Andrews JM
    J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones.
    Balcabao IP; Alou L; Aguilar L; Gomez-Lus ML; Giménez MJ; Prieto J
    J Antimicrob Chemother; 2001 Dec; 48(6):907-9. PubMed ID: 11733477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.